Broadening our impact
DLL3
Our lead program targets DLL3, a cell-surface protein widely expressed across a range of cancers, with limited expression on healthy cells. This selective expression makes DLL3 an ideal target for treating these aggressive cancers, which today have poor survival rates.
B7-H3
Our second program targets B7-H3, which is highly expressed across many types of cancer and correlates with poor patient survival and prognosis. B7-H3 has been shown to promote tumor cell proliferation and metastases and help tumor cells evade the immune system.
Discovery programs
Our selection of novel targets and innovative approach to designing compounds and radioligand therapies fuel a robust portfolio of early-stage programs, each with the potential to address a broad range of cancers. Lead candidates are engineered for selective target binding, tumor penetration, and rapid clearance of unbound molecules for treatments with high impact on tumors and minimal unwanted side effects.
We're strategically pursuing cancer targets that unlock the full potential of radioligand therapy. By taking an innovative, tailored approach to drug design and development for each high-impact target, we aim to precisely deliver radiation where it matters most, expanding the therapeutic reach of radioligand therapies across multiple cancer types of unmet need.”
Gökben Koca, Chief Medical Officer